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Abstract
Background: Colorectal cancer (CRC) is a leading cause of cancer-related deaths in developed countries and its
incidence increases with age. Intravenous administration of bolus 5-fluorouracil (5-FU) and leucovorin (LV) has been
a standard treatment regime for stage III CRC. However, patients generally prefer oral therapy such as Capecitabine.
Studies showed that combination of oxaliplatin and capecitabine demonstrated efficacy and safety on par with
treatment involving various 5-FU/LV-based regimens in elderly patients as they are in younger ones. However, little
is known regarding the cost of adjuvant therapy or the effect of therapy on HRQoL. Thus the aims of this study
were to evaluate the influence of different adjuvant care for stage III CRC on the HRQoL of elderly patients and to
compare the economic costs associated with capecitabine-based and 5-FU/LV-based adjuvant treatments from a
societal perspective in Taiwan.
Methods: A prospective, open-label, observational, multicenter study involving 123 patients aged 70 and over from
11 different centers was conducted between July 2008 and July 2011 in Taiwan. The adjusted monthly costs per
patient and HRQoL were evaluated from individual-level data. The HRQoL of patients was assessed before and after
adjuvant treatment. Direct and indirect costs of adjuvant treatment were estimated from a number of sources, and
QoL scores were compared between groups.
Results: After correcting for baseline characteristics of patients, no significant differences were observed in the global
HRQoL scores between treatment groups during the study period. According to QLQ-CR38 results, capecitabine-based
therapy appeared to alleviate problems related to defecation (4.54 vs. 8.5; P = 0.011); however, micturition problems
increased (9.27 vs. 7.51; P = 0.04), compared with 5-FU/LV-based treatment. The adjusted monthly treatment cost per
patient was NT$27,300 for capecitabine-based treatment and NT$53,671 for 5-FU/LV-based treatment. The total cost of
5-FU/LV-based treatment was 59 % greater than that of capecitabine-based treatment.
Conclusions: Analyzing from the societal perspective in Taiwan, capecitabine-based therapy incurred lower treatment
costs than 5-FU/LV-based therapy and did not jeopardize HRQoL. Therefore, capecitabine, with or without oxaliplatin,
could be considered as an alternative treatment option for elderly patients with stage III CRC.
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Background
Colorectal cancer (CRC) is a leading cause of cancer-
related deaths in developed countries and its incidence
increases with age. Every year, approximately 1 million pa-
tients are diagnosed with CRC and half a million deaths are
attributed to this disease worldwide [1]. In Taiwan, CRC is
the second most frequently diagnosed cancer and the third
leading cause of cancer-related death, after lung and liver
cancer. The incidence of CRC in Taiwan has been increas-
ing over the last 2 decades, with 11,004 cases recorded in
2008 [2]. Age-standardized mortality for CRC was 44 per
100,000 for men and 32 per 100,000 for women. Nearly
45 % of CRC patients are aged above 70 years, and the me-
dian age at death from advanced CRC is 73 years [3]. In the
United States (US), national expenditures related to CRC
care amounted to 12.16 billion dollars and lost productivity
owing to deaths caused by CRC amounted to 10.65 billion
dollars in 2010 [4]. With an aging population, CRC is ex-
pected to become increasingly common among older indi-
viduals, and subsequently increase the burden on health
care resources.
Surgery remains the most common treatment for CRC;
53.1 % of all CRC patients in the US have undergone sur-
gery [5]. Adjuvant chemotherapy after tumor resection is
now considered a standard treatment for stage III CRC to
prevent recurrence and prolong survival [6]. Compared to
surgery alone, adjuvant chemotherapy or radiotherapy im-
proves overall survival and reduces the probability of CRC
recurrence. However, chemotherapy has been provided
less frequently to elderly patients than those in other age
groups [7].
Intravenous administration of bolus 5-fluorouracil (5-FU)
and leucovorin (LV), either weekly or monthly over a
period of 6 to 8 months, has been a standard treatment re-
gime for stage III CRC [8]. The results from landmark trials
have shown a 22 % reduction in mortality due to 5-FU/LV
treatment versus surgery alone [9]. Adjuvant 5-FU/LV re-
duces the risk of relapse and prolongs patient survival after
surgery [10]. Although the clinical benefits of adjuvant 5-
FU/LV-based treatment are significant, data suggest that
patients generally prefer oral therapy to intravenously ad-
ministered treatments [11].
Capecitabine is an oral fluoropyrimidine designed to
deliver 5-FU to tumor tissue. Many studies have shown
that, when used an adjuvant treatment for stage III CRC,
capecitabine therapy is at least as effective and well
tolerated as 5-FU/LV alone [12]. These trials further de-
termined that capecitabine provided equivalent disease-
free survival (DFS) and overall survival (OS) rates among
patients aged ≥70 years [13]. In a series of studies on
stage II/III CRC, combination oxaliplatin and capecita-
bine chemotherapy demonstrated efficacy and safety on
par with treatment involving various 5-FU/LV-based reg-
imens [14].
To gain a better understanding of how cancer, surgery,
and adjuvant therapy influence patient outcomes, objective
clinical endpoints, including survival, postoperative disabil-
ity, or death are increasingly being augmented by data asso-
ciated with health-related quality-of-life (HRQoL). The
American Society of Clinical Oncology considers that pa-
tient outcomes such as toxicity, survival, and HRQoL are
more important than cancer outcomes. Thus, HRQoL as-
sessment is essential to the clinical decision-making process
as it provides insights regarding patient experience with
disease and treatment [15]. Commella and colleagues com-
pared oral capecitabine plus oxaliplatin and 5-FU/LV plus
oxaliplatin treatments for MCRC patients [16], and found
that there were no differences in the QoL of patients
treated using these regimens. Venderbosch et al. evaluated
the effect of first-line capecitabine monotherapy and other
capecitabine combination treatments in different age
groups with MCRC [17]. The results showed that among 3
patient age groups (>75, 70–75 and <70 years), there were
no differences in global QoL. Hus and colleagues estimated
the cost-effectiveness of oral capecitabine in the adjuvant
treatment of stage III colon cancer patients in Taiwan [18].
With regard to the perspectives of the National Health In-
surance Administration (NHIA) and society in Taiwan, they
found that capecitabine treatment was less expensive than
5-FU/LV, and the overall direct cost with capecitabine treat-
ment was less than that with 5-FU/LV (NT$129,327 vs.
NT$233,873) during the 24-week treatment period. Lang
and colleagues estimated that the undiscounted, average
10-year cancer-related medical care cost for CRC was
NT$584,985 in 2002 [19].
Previous studies have demonstrated that the clinical
benefits from adjuvant treatments are at least as signifi-
cant in elderly patients as they are in younger ones.
However, little is known regarding the cost of adjuvant
therapy or the effect of therapy on HRQoL. Thus the
aims of this study were to evaluate the influence of dif-
ferent adjuvant care for stage III CRC on the HRQoL of
elderly patients and to compare the economic costs as-
sociated with capecitabine-based and 5-FU/LV-based ad-
juvant treatments from a societal perspective in Taiwan.
Methods
Ethical standards
The study was approved by the ethics board of each in-
stitution: Taipei Veterans General Hospital (approval
numbers: 98-06-26A), Shin Kong Wu Ho-Su Memorial
Hospital (approval numbers: 97E-018), Cathay General
Hospital (approval numbers: CT9738), Mackay Memorial
Hospital (approval numbers: MM-I-S-607H), Chia-Yi Chris-
tian Hospital (approval numbers: 97040), Changhua Chris-
tian Hospital (approval numbers: CCH081009), National
Cheng Kung University Hospital (approval numbers: ER-97-
116), China Medical University Hospital (approval numbers:
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DMR97-IRB-156), Taipei Municipal Wanfang Hospital (ap-
proval numbers: 97043), Chiayi Chang Gung Memorial
Hospital and Kaohsiung Chang Gung Memorial Hospital
(approval numbers: 972003B [for two hospitals with a com-
mon ethics board]). All the participants gave written in-
formed consent prior to the commencement of the study.
Patient population
This study included 11 institutions: 9 academic medical
centers and 2 regional hospitals. Patients aged 70 and over
with stage III CRC, as confirmed by physicians or by a
pathological examination in these institutions, and who
underwent potentially curative resection of the tumor
were eligible for the study. In addition, patients had to be
prescribed capecitabine or 5-FU/LV, either with or with-
out or oxaliplatin.
Patients who had a history of other malignancies during
the study period were excluded from this study. Other ex-
clusion criteria were participation in any investigational
drug study 4 weeks before the start of the treatment, hav-
ing received adjuvant radiotherapy in combination with
chemotherapy after resection, or any changes in the use of
study drugs during the period of study.
Study design
This was a prospective, open-label, observational, multi-
center study. The objectives were to evaluate changes in
HRQoL and to determine the costs of various adjuvant
treatments administered to stage III CRC patients. Demo-
graphic data and clinical characteristics as well as HRQoL
and cost data were collected for analysis.
Two adjuvant chemotherapy regimens were administered
and tested: capecitabine with or without oxaliplatin (case
group) and 5-FU/LV with or without oxaliplatin (compari-
son group). We collected patients’ demographic character-
istics, including age, gender, education level, marital status,
work status and family history, when interviewing at base-
line survey. Their clinical characteristics including comor-
bidity, used oxaliplatin or not and with stoma or not were
collected by chart review. We recorded the baseline values
for HRQoL before treatment as well as 30 days after treat-
ment, rather than immediately after treatment, because
HRQoL status remains in a state of transition owing to the
ongoing effects of medication. Treatment was continued
for 6 months or until disease remission, whichever oc-
curred first.
Between July 2008 and December 2010, eligible patients
were assigned to either the capecitabine or 5-FU/LV treat-
ment group by their oncologist and followed up for
7 months, until the clinical cut off in July 2011. In Taiwan,
the chemotherapy treatment could be administered either
in an inpatient setting or using a chemotherapy pump
with 72 h infusion depending on patient’s age, capable to
take care chemo pump and distance from their home to
the hospital. In order to capture the real utilization of
CRC patient received adjuvant treatment, all utilization
including frequency of outpatient visit and number of
admissions, length of stay of each hospitalization and so
on were collected. The total duration of the study was
25 months. Questionnaires were administrated by nurses,
all of whom were actively involved in the study, at each
hospital and filled out by each patient. Nurses provided
assistance in filling out the questionnaires when necessary.
HRQoL measures
The questionnaires frequently used to assess the HRQoL of
CRC patients are the QoL QLQ-C30, developed by the
European Organization for Research and the Treatment of
Cancer (EORTC), the Chinese version of this document
[20], the colorectal module QLQ-CR38 [21], and the Func-
tional Assessment of Cancer Therapy-General version
(FACT-G). According to Uwer et al., the EORTC QLQ-
C30 is well suited for evaluating patients receiving chemo-
therapy and the colorectal module QLQ-CR38 provides
additional clinically relevant information. Therefore, we se-
lected the EORTC QLQ-C30 and QLQ-CR38 question-
naires to investigate the HRQoL of the CRC patients.
The former contains 30 questions, subdivided into 5
functional levels (physical, role, emotional, cognitive,
and social), 9 symptom scales (fatigue, nausea and
vomiting, pain, dyspnea, insomnia, appetite loss, consti-
pation, diarrhea, and financial difficulties) as well as a
single global QoL scale. Scores are summed and trans-
formed to a value ranging from 0 to 100 based on the
EORTC QLQ-C30 scoring manual [22]. A high score on
the functional scale represents a high level of function
in daily life, a high score on the global QoL scale repre-
sents a high QoL, and a high score on the symptom
scale represents a high level of symptomatology or other
health problems.
The EORTC QLQ-CR38 comprises 38 questions, of
which 19 were completed by all study participants, while
the remaining 19 questions were divided into groups rele-
vant to various subsets of patients (e.g., male or female, the
presence or absence of stoma). This questionnaire is subdi-
vided into 4 functional scales (body image, sexual function-
ing, sexual enjoyment, and future perspective), 8 symptom
scales (micturition problems, gastrointestinal tract symp-
toms, chemotherapy side effects, defecation problems,
stoma-related problems, male and female sexual problems,
and weight loss). The validity and reliability of this tool has
been established in a study involving Dutch CRC patients.
The scoring for this questionnaire involves the same meth-
odology as that used for the EORTC QLQ-C30 question-
naire [22].
Questionnaire manuals dictate that missing values
should be dealt with as follows: if at least half of the items
on a scale are completed, the scale score is divided by the
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number of items present; if fewer than half of the items
are completed, the scale is considered missing.
Minimum important difference (MID)
MID is defined as the smallest difference in score for the
domain of interest, which is considered important by pa-
tients (beneficial or harmful) and would lead a clinician to
consider altering the course of treatment. With regard to
the EORTC QLQ-C30, Osoba et al. suggested that an
MID of more than 10 points between baseline and any
subsequent visit could be considered a clinically significant
change [23].
Direct medical and non-medical costs
For this study, CRC patients (ICD-9-CM codes: 153, 154)
were defined as those who received capecitabine-based or
5-FU/LV-based treatment after surgery. Patients who
received post-surgical radiotherapy were excluded. Data
related to use and expenditure related to medical and
non-medical services were collected directly from self-
administered questionnaires. Patients were asked to recall
events related to treatment episodes. This study gathered
the medical utilization records of patients, including out-
patient visits related to chemotherapy, other outpatient
visits, length of inpatient chemotherapy stay, emergency
visits, and treatment for adverse events. The average ex-
penditure related to each of these services was calculated
from records obtained from the Longitudinal National
Health Insurance Research Database (NHIRD) for 2007
and 2008. This database contains data on hospital admis-
sion and ambulatory visits, primary and community care
services as well as prescribed medication for the 1 million
individuals covered under the comprehensive reimburse-
ment schemes of the National Health Insurance Administra-
tion in Taiwan. Finally, direct medical costs were obtained
by multiplying the average medical expense by the number
of instances of each type of medical service.
Direct non-medical utilization costs include the cost of
transportation associated with receiving medical care, home
nursing fees, and special supplements or food required dur-
ing treatment. Direct non-medical costs were also deter-
mined from self-administered questionnaires. All the costs
were adjusted for patient’s demographic and clinical charac-
teristics listed in Table 1 by multivariate linear regression
and were not discounted during study period.
Societal costs
We estimated the cost of lost patient productivity associ-
ated with receiving outpatient or inpatient care. We also es-
timated the cost of lost productivity for relatives who
accompanied patients to treatment events. The followings
are the formulas of calculating: (1) loss of productivity in-
curred by patients who received outpatient visit or inpatient
care; and (2) loss of productivity of accompanying relatives:
(1).Loss of productivity of patients receiving outpatient
or inpatient care = (Average income * Labor force
participation rate*(1- Unemployment rate)/Average
work hours (181.2 h))*Time spent for medical
treatment
(2).Loss of productivity of accompanying relatives
= (The minimum wage in 2010 (NT$ 17280)/
Average work hours (181.2 h))*Time spent for
accompanying
These data was retrieved from the self-administered
questionnaire and expected losses were calculated as in-
come loss. In accordance with the human capital ap-
proach, expected losses in productive time were translated
into monetary terms. The age- and sex-specific average in-
come, labor force participation rates, and unemployment
rates were obtained from the 2010 Report on the Man-
power Utilization Survey to estimate lost productivity for
accompanying relatives [24].
Statistical methods
Descriptive analysis was used to compare baseline charac-
teristics between groups undergoing capecitabine- and
5-FU/LV-based treatments. Categorical variables were
summarized in frequency tables, and continuous and
other numeric variables were summarized by presenting
the number of observations, the mean value, and the
standard deviation. Student t-test and Pearson chi-square
test were used to examine the statistical significance of
baseline characteristics between these two groups. Paired
t-test was used to examine the HRQoL scores between
baseline and the 28th week of these two treatments. A
mixed model adjusting for patient demographic and clin-
ical factors was assembled to test the change in HRQoL
from baseline to 28th week between these two groups.
Results
A total of 123 elderly patients (capecitabine group, n = 93;
5-FU/LV group, n = 30) completed all 3 surveys. The char-
acteristics of these patients at baseline are presented in
Table 1. After adjustment, 108 of the patients were in-
cluded in the analyses (81 from the capecitabine group
and 27 from the 5-FU/LV group). There was a significant
difference with respect to age, gender, education, family
history, and use of oxaliplatin between patients receiving
capecitabine- and 5-FU/LV-based treatments. Compared
with the 5-FU/LV group, patients in the capecitabine
group were older (77.47 vs. 75.27 years; P = 0.021), had a
higher percentage of female patients (50.54 % vs. 20.00 %;
P = 0.005) and junior high school graduates (90.22 % vs.
62.07; P = 0.002), had a lower frequency of family history
of cancer (82.42 % vs. 79.31 %; P = 0.04), and were less
frequently administered oxaliplatin (88.17 % vs. 33.33 %;
P < 0.0001).
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General HRQoL
A comparison of the EORTC QLQ-C30 results between
the capecitabine and 5-FU/LV groups is presented in
Table 2. After corrections for age, gender, education, marital
status, employment status, tumor site, family history, co-
morbidities, and use of oxaliplatin during adjuvant treat-
ment, no significant differences were observed between the
2 groups at baseline. Significant improvements in physical
function, role function, emotional function, global health
status, and fatigue were reported by both groups between
baseline and the final visit. Compared with the 5-FU/LV-
based treatment group, patients in the capecitabine-based
treatment group showed significant improvements in cog-
nitive function, pain, dyspnea, and insomnia, but signifi-
cantly reduced social function between baseline and the
final visit. We also analyzed the adjusted means in the final
Table 1 Characteristics of stage III CRC in elderly patients
Variable Capecitabine group 5-FU/LV group P value
n % n %
n 93 75.61 30 24.39
Age (mean, SD) a (77.47, 4.53) (75.27, 4.35) 0.021
Gender b
Male 46 49.46 24 80.00 0.005
Female 47 50.54 6 20.00
Education b
No more than junior high school 83 90.22 18 62.07 0.002
Senior high school 6 6.52 7 24.14
University or above 3 3.26 4 13.79
Marital status b
Married or cohabiting 70 81.40 25 83.33 1.000
Other 16 18.60 5 16.67
Employment status b
Unemployed 90 96.77 26 89.66 0.1453
Employed 3 3.23 3 10.34
Tumor site b
Colon 77 82.80 19 63.33 0.784
Rectum 16 17.20 11 36.67
Family history of cancer b
No 75 82.42 23 79.31 0.040
Yes 16 17.58 6 20.69
Comorbidity b
None 27 29.67 10 33.33 0.820
Hypertension 37 40.66 10 33.33 0.524
CAD 8 8.79 3 10.00 1.000
CVA 9 9.89 - - 0.110
Renal insufficiency 6 6.59 2 6.67 1.000
DM 18 19.78 6 20.00 1.000
COPD 3 3.30 1 3.33 1.000
Liver cirrhosis 5 5.49 - - 0.331
Other comorbidity 27 29.67 8 26.67 0.820
Oxaliplatin administered b
No 82 88.17 10 33.33 < 0.0001
Yes 11 11.83 20 66.67
Abbreviations: CAD coronary artery disease, CVA cardiovascular disease, DM diabetes mellitus, COPD chronic obstructive pulmonary disease
a Student t-test was used to calculate the statistical significance at the 5 % level
b Pearson chi-square test was used to calculated the significance at the 5 % level
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Table 2 Results for health-related quality of life from the QLQ-C30
Dimensions Capecitabine-based 5-FU/LV-based P
valuebn Mean SD P valuea n Mean SD P valuea
Physical
Baseline 81 73.90 11.78 27 80.12 12.46 0.746
28th week 81 86.14 11.13 <0.0001 27 86.12 11.48 0.038 0.657
Role
Baseline 81 78.58 11.65 27 77.48 14.78 0.865
28th week 81 90.97 11.08 <0.0001 27 86.77 14.31 0.001 0.582
Emotional
Baseline 81 84.45 8.54 27 83.88 7.57 0.537
28th week 81 90.24 7.56 <0.0001 27 89.93 6.10 <0.0001 0.357
Cognitive
Baseline 81 88.18 7.42 27 88.58 8.30 0.091
28th week 81 92.55 7.29 <0.0001 27 87.77 6.93 0.641 0.331
Social
Baseline 81 83.15 8.58 27 82.75 11.85 0.313
28th week 81 84.86 9.06 0.226 27 91.03 8.98 0.002 0.532
Global health status
Baseline 81 62.93 6.59 27 59.61 8.98 0.517
28th week 81 75.58 5.64 <0.0001 27 74.76 4.97 <0.0001 0.854
Fatigue
Baseline 81 25.11 10.49 27 25.80 8.81 0.884
28th week 81 9.34 10.53 <0.0001 27 17.59 9.63 0.002 0.259
Nausea and Vomiting
Baseline 81 3.91 9.41 27 6.77 10.74 0.467
28th week 81 6.56 9.96 0.002 27 6.81 10.89 0.982 0.187
Pain
Baseline 81 11.75 8.36 27 8.41 7.61 0.421
28th week 81 4.63 6.24 <0.0001 27 4.07 6.13 0.058 0.746
Dyspnea
Baseline 81 8.82 8.62 27 6.00 9.61 0.087
28th week 81 6.64 5.13 0.029 27 4.90 8.52 0.536 0.689
Insomnia
Baseline 81 22.16 15.78 27 18.50 13.71 0.050
28th week 81 16.15 11.96 0.002 27 17.19 11.73 0.603 0.382
Appetite loss
Baseline 81 10.44 10.91 27 19.64 12.17 0.004
28th week 81 11.10 14.75 0.696 27 11.67 16.08 0.006 0.476
Constipation
Baseline 81 14.31 12.40 27 6.36 11.67 0.057
28th week 81 14.28 7.64 0.982 27 6.24 6.53 0.951 0.273
Diarrhea
Baseline 81 13.88 16.39 27 13.82 14.39 0.581
28th week 81 9.05 14.78 0.002 27 12.91 13.16 0.783 0.276
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visit after correction for patient characteristics and QLQ -
C30 scores at baseline, after which no significant differences
were observed between the results of the 2 groups.
Cancer-specific HRQoL
A comparison of the EORTC QLQ - CR38 results be-
tween the capecitabine- and 5-FU/LV-based treatment
groups is shown in Table 3. Patients in the capecitabine-
based group suffered fewer side effects of chemotherapy
(6.92 vs. 16.79; P = 0.003) and fewer problems related to
defecation (5.38 vs. 9.05; P = 0.025) at baseline. After
correction for patient characteristics and baseline HRQoL
scores, patients in the capecitabine group still suffered
fewer problems with defecation (4.54 vs. 8.5; P = 0.011);
however, they experienced more micturition-related diffi-
culties (9.27 vs. 7.51; P = 0.04) than the 5-FU/LV group in
the final visit.
Societal prospective-direct and indirect costs
The monthly societal costs for the capecitabine and 5-
FU/LV groups during adjuvant chemotherapy are sum-
marized in Table 4. The total cost per patient in the 5-
Table 2 Results for health-related quality of life from the QLQ-C30 (Continued)
Financial difficulties
Baseline 81 6.06 6.70 27 7.45 7.24 0.666
28th week 81 6.05 10.20 0.990 27 4.83 10.33 0.118 0.040
a Paired t-test was used to calculate the statistical significance at the 5 % level between the adjusted means at baseline and the 28th week
b Mixed model was used to calculate the statistical significance at the 5 % level following adjustment for patient age, gender, education, marital status, work
status, tumor site, family history, comorbidities, use of oxaliplatin, and baseline HRQoL score
Table 3 Results for health-related quality of life from the QLQ-CR38 questionnaire
Capecitabine-based 5-FU/LV based P
valuebn Mean SD P valuea n Mean SD P valuea
Body image
Baseline 81 97.38 6.14 27 92.53 7.50 0.174
28th week 81 98.04 8.25 0.274 27 94.05 7.68 0.120 0.257
Future perspective
Baseline 81 54.52 15.93 27 66.70 18.30 0.135
28th week 81 67.66 13.61 <0.0001 27 67.70 15.49 0.769 0.422
Sexual functioning
Baseline 81 83.15 8.58 27 82.75 11.85 0.313
28th week 81 84.86 9.06 0.226 27 91.03 8.98 0.002 0.159
Micturition
Baseline 81 14.23 8.44 27 13.50 7.46 0.891
28th week 81 9.27 6.88 <0.0001 27 7.51 6.33 0.000 0.040
Chemotherapy side effects
Baseline 81 6.92 7.03 27 16.79 8.37 0.003
28th week 81 7.50 7.38 0.635 27 11.50 8.03 0.008 0.706
Gastrointestinal tract
Baseline 81 9.27 7.79 27 12.24 7.55 0.277
28th week 81 4.42 6.90 <0.0001 27 6.09 6.56 <0.0001 0.163
Defecation problems
Baseline 81 5.38 11.46 27 9.05 9.60 0.025
28th week 81 4.54 7.14 0.205 27 8.50 5.52 0.683 0.011
Weight loss
Baseline 81 16.41 13.31 27 24.86 14.73 0.973
28th week 81 6.42 12.41 <0.0001 27 7.47 8.52 <0.0001 0.309
a Paired t-test was used to calculate the statistical significance at the 5 % level between the adjusted means at baseline and the 28th week
b Mixed model was used to calculate the statistical significance at the 5 % level after adjustment for patient age, gender, education, marital status, work status,
tumor site, family history, comorbidities, use of oxaliplatin, and baseline HRQoL score
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FU/LV group was higher than that in the capecitabine
group, with respect to both direct costs (medical and
non-medical expenditures) and indirect costs (loss of
productivity for the patient and accompanying relatives).
After correction for patient characteristics, the per-
patient costs in the capecitabine group amounted to
NT$17,200.46 (direct) and NT$27,299.60 (indirect), to-
taling to NT$42,372.52 per patient in monthly societal
costs. The per-patient costs in the 5-FU/LV group were
NT$42,372.52 (direct) and NT$11,298.55 (indirect), to-
taling to NT$53,671.07 per patient in monthly societal
costs. Differences in expenditures associated with in-
patient chemotherapy and side effects had the greatest
influence on incremental costs in the 5-FU/LV arm.
Discussion
The benefits of adjuvant treatment include reduced risk
of relapse and prolonged survival but the side effects
and complications often reduce the QoL for the patients.
Although many studies have employed HRQoL measure-
ments when studying CRC patients, however, only few
studies addressed the impact of adjuvant treatments on
HRQoL and the associated costs of caring for the elderly
patients. To the best of our knowledge, this is the first
study to examine both the QoL and societal cost with
regard to the influence of adjuvant treatment on stage
III colon and rectal cancer for patients aged ≥70 years.
Results from the EORTC QLQ-C30 and CR-38 ques-
tionnaires demonstrated that capecitabine-based therapy
was not inferior to 5-FU/LV-based therapy in terms of
QoL. Moreover, patients undergoing capecitabine-based
therapy incurred low treatment costs and showed im-
proved conserved productivity. The QLQ-C30 question-
naire showed no difference in the QoL between groups,
while the QLQ-CR38 indicated that the capecitabine
group experienced problems associated with defecation
and micturition after treatment.
Our results are in agreement with a randomized factor-
ial trial involving elderly and frail MCRC patients con-
ducted in the UK which showed no differences in the QoL
between patients receiving capecitabine (with or without
oxaliplatin) and those receiving fluoropyrimidines (with or
without oxaliplatin) [25]. A randomized phase III study,
conducted in France, produced similar results, i.e., no sig-
nificant difference in QLQ-C30 scores between patients
undergoing XELOX or FOLFOX-6 treatment [26]. In the
current study, after adjuvant therapy, both groups showed
significant improvement in global health status, and no
clinically relevant difference was found between these
groups in the sub-categories in either the QLQ-C30 or
QLQ-CR38 questionnaires. These results are not surpris-
ing, considering that capecitabine-based treatment (with
or without oxaliplatin) and 5-FU/LV-based treatment
(with or with oxaliplatin) have similar safety and efficacy
profiles with regard to the elderly [27]. Finally, baseline
QLQ-C30 and QLQ-CR38 scores were similar in the cap-
ecitabine and 5-FU/LV arms, except for the loss of appe-
tite, side effects of chemotherapy, and problems with










Mean (SD) Mean (SD)
Direct cost
Medical cost
Ambulatory cost 6410.32 (4116.36) 4636.80 (5041.69) −1773.52 0.0548 −603.50 0.2981
Outpatient chemotherapy cost 2856.64 (6854.69) 10626.70 (17649.99) 7770.06 0.0249 1994.60 0.2555
Inpatient chemotherapy cost 462.59 (3200.74) 26386.21 (24329.36) 25923.62 <0.0001 14718.53 0.0009
Side effects of treatment cost 151.49 (1027.40) 11857.91 (10068.21) 11706.42 <0.0001 7324.83 <0.0001
Non-medical cost
Travel cost 51.56 (64.34) 56.67 (138.52) 5.11 0.8464 2.52 0.8906
Nursing aide 397.85 (2863.34) 1366.67 (4802.90) 968.82 0.3023 723.86 0.0121
Alternative care 56.99 (333.10) - −56.99 0.1024 −46.21 0.0086
Total direct cost per patient 10387.44 (9016.48) 54930.95 (27747.10) 44543.51 0.3374 25172.06 <0.0001
Indirect cost
Loss of productivity 862.01 (1250.5) 1654.77 (1168.69) 792.76 0.003 140.27 0.411
Loss of productivity for accompanying relatives 6502.90 (9445.88) 12474.00 (8802.9) 5971.10 0.003 1059.14 0.411
Total indirect cost per patient 7364.91 (10696.38) 14128.77 (9971.59) 6763.86 0.003 1199.41 0.411
Total cost per patient 17752.35 (12907.36) 69059.72 (26313.49) 51307.37 <0.0001 26371.47 <0.0001
* Values greater than zero reflect a higher monthly expenditure during 5-FU/LV regimens
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defecation. Patients in the capecitabine group experienced
far less problems from these conditions than those in the
5-FU/LV group. However, with a difference in scores less
than the MID of 10 points, the discrepancies are not clin-
ically relevant.
Many studies have reported that capecitabine-based treat-
ment is less expensive than other treatment regimens. One
study conducted in the US showed that non-Medicare CRC
patients treated with capecitabine had lower monthly total
direct medical (US$740) and chemotherapy-related ex-
penses (US$785) than patients treated with 5-FU/LV [28].
Another cost comparison reported that the monthly ex-
penditure per patient for capecitabine (US$6,683) or capecit-
abine/oxaliplatin (US$11,436) treatment was significantly
lower than that for 5-FU/LV (US$9,304) or 5-FU/LV/oxali-
platin (US$14,320) treatment [29]. A cost-benefit analysis
conducted in the Netherlands showed that the monthly ad-
juvant treatment costs were €3,770 for capecitabine and
€4,704 for 5-FU/LV [30]. In the UK, a cost-minimization
study reported that the treatment costs for oral capecitabine
(£2,132) were lower than those for the Mayo regimen
(£3,593) over the same treatment period [31]. However, few
studies provide a reasonable comparison between oral and
intravenous chemotherapy costs for elderly CRC patients. In
line with the findings of these studies, our results suggest
that the use of capecitabine-based adjuvant chemotherapy
after tumor resection in elderly patients with stage III colon
cancer reduces societal costs, as compared to 5-FU/LV-
based therapy. The adjusted monthly cost saving per patient
is NT$26,372 (US$879) when a capecitabine-based treat-
ment is used, mainly because of the significantly lower costs
of inpatient chemotherapy and AE-related expenditure. In
addition, our results show that patients treated with
capecitabine-based therapy experienced a smaller loss of
productivity that those treated with 5-FU/LV-based therapy.
When interpreting these results, several issues should
be considered. First, the current study was an observa-
tional, non-randomized study. Although it reflects the
actual use of societal resources for patient care, it is still
subject to bias. The allocation of resources for specific
treatment methods might have been biased by patient
characteristics or socio-economic status. Therefore, we
used a mixed model to adjust for potential bias. Second,
very few patients responded to the sexual health-related
dimensions of the QLQ-CR38 questionnaire. Therefore,
the influence of treatment method on sexual enjoyment
and sexual problems on the groups was not investigated.
Third, the imbalance in these two groups might have
impact on detecting a change of HRQoL scores. How-
ever, considering the MID of EORTC QLQ-C30, the es-
timate of power of this model was almost 0.99 which is
enough to detect the change of HRQoL scores of pa-
tients between these two arms. Fourth, there is no sug-
gested MID for the EORTC QLQ-CR38. We may
identify the statistical difference, instead of clinical dif-
ference, between capecitabine-based therapy and 5/FU/
LV-based therapy. Fifth, 66 % of the 5-FU/LV-based
group combined with oxaliplatin therapy but only 11 % of
the capecitabine-based group received oxaliplatin. The re-
sults of the study also indicated that the number of side
effects in the capecitabine-based group was 0.02 ± 0.15
and was 1.68 ± 1.43 in the 5-FU/LV-based group. The oc-
currence of side effects may have potential influence on
efficacy and toxicity, and consequently reflected on pa-
tient’s HRQoL and treatment costs.
Conclusions
To the best of our knowledge, this is the first study to
gather HRQoL and cost data from elderly patients at the
individual level. Capecitabine-based therapy can be con-
sidered superior to 5-FU/LV-based therapy in terms of
cost and at least as effective in terms of QoL when treat-
ing elderly patients with stage III CRC patients. There-
fore, from both clinical and economic viewpoint, the
capecitabine-based regimen, with or without oxaliplatin,
could be considered as an appropriate alternative to the
5-FU/LV-based regimen.
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